Rhumbline Advisers Boosts Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

Rhumbline Advisers grew its position in scPharmaceuticals Inc. (NASDAQ:SCPH) by 20.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 42,554 shares of the company’s stock after purchasing an additional 7,112 shares during the period. Rhumbline Advisers’ holdings in scPharmaceuticals were worth $151,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in SCPH. Thrivent Financial for Lutherans grew its stake in shares of scPharmaceuticals by 1.4% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock valued at $4,783,000 after buying an additional 14,866 shares during the period. King Luther Capital Management Corp grew its stake in shares of scPharmaceuticals by 0.9% in the 3rd quarter. King Luther Capital Management Corp now owns 2,225,790 shares of the company’s stock valued at $10,150,000 after buying an additional 20,650 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in shares of scPharmaceuticals in the 3rd quarter valued at approximately $57,000. BNP Paribas Financial Markets boosted its position in shares of scPharmaceuticals by 116.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock worth $26,000 after purchasing an additional 3,101 shares during the period. Finally, Rubric Capital Management LP boosted its position in shares of scPharmaceuticals by 35.5% during the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after purchasing an additional 1,250,000 shares during the period. Hedge funds and other institutional investors own 89.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on SCPH. Craig Hallum lowered their price objective on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a research report on Monday, March 3rd.

scPharmaceuticals Stock Performance

NASDAQ:SCPH opened at $2.89 on Tuesday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. The stock has a market capitalization of $144.62 million, a P/E ratio of -1.52 and a beta of 0.40. The company has a 50 day moving average price of $3.37 and a 200 day moving average price of $3.91. scPharmaceuticals Inc. has a fifty-two week low of $2.75 and a fifty-two week high of $6.20.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.